We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
201
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$822K 0.05%
26,027
-33,973
-57% -$1.2M
NUVA
202
DELISTED
NuVasive, Inc.
NUVA
$812K 0.04%
15,000
-20,000
-57% -$1.02M
BGMS
203
Bio Green Med Solution Inc
BGMS
$4.8M
$755K 0.04%
2
-1
-33% -$507K
NGNE icon
204
Neurogene
NGNE
$653M
$753K 0.04%
3,016
+16
+0.5% +$4.21K
CLVS
205
DELISTED
Clovis Oncology, Inc.
CLVS
$732K 0.04%
+20,923
New +$1.35M
RXDX
206
DELISTED
Ignyta, Inc.
RXDX
$725K 0.04%
54,099
-198,875
-79% -$2.4M
PVCT
207
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$724K 0.04%
1,856,019
-126,118
-6% -$59.8K
BITI
208
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$714K 0.04%
50,460
+10,460
+26% +$146K
CTIC
209
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$708K 0.04%
+57,567
New +$769K
CTIC
210
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$707K 0.04%
575
– –
GWPH
211
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$694K 0.04%
100
– –
ADMS
212
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
$688K 0.04%
+243
New +$4.09K
BLCM
213
PUT
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$659K 0.04%
33
– –
NURO
214
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$650K 0.04%
513
+172
+50% +$306K
CLRB icon
215
Cellectar Biosciences
CLRB
$20.5M
$633K 0.03%
29
+16
+123% +$679K
KPRX icon
216
Kiora Pharmaceuticals
KPRX
$11.3M
$624K 0.03%
42
-3
-7% -$48.4K
LRMR icon
217
CALL
Larimar Therapeutics
LRMR
$387M
$617K 0.03%
82
+2
+3% +$321
MTEM
218
DELISTED
Molecular Templates, Inc.
MTEM
$609K 0.03%
+7,689
New +$3.79M
PTLA
219
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$602K 0.03%
+117
New +$5.67K
CPXX
220
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$594K 0.03%
+337,462
New +$579K
INSM icon
221
CALL
Insmed
INSM
$22.6B
$592K 0.03%
326
-185
-36% -$3.26K
CARM
222
DELISTED
Carisma Therapeutics
CARM
$584K 0.03%
9,702
+1,125
+13% +$63.9K
CAPR icon
223
Capricor Therapeutics
CAPR
$380M
$570K 0.03%
18,566
-6,479
-26% -$258K
ITCI
224
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$538K 0.03%
100
-1,278
-93% -$64.5K
OCAT
225
PUT
DELISTED
OCATA THERAPEUTICS, INC. COMMON STOCK
OCAT
$525K 0.03%
+624
New +$4.18K
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.